Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study

James Bluett, Jamie Sergeant, Alex MacGregor, Jacqueline Chipping, Tarnya Marshall, Deborah Symmons & Suzanne Verstappen
Abstract Background Oral methotrexate (MTX) is the first-line therapy for patients with rheumatoid arthritis (RA). However, approximately one quarter of patients discontinue MTX within 12 months. MTX failure, defined as MTX cessation or the addition of another anti-rheumatic drug, is usually due adverse event(s) and/or inefficacy. The aims of this study were to evaluate the rate and predictors of oral MTX failure. Methods Subjects were recruited from the Norfolk Arthritis Register (NOAR), a primary care-based...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.